Biotech investors’ plea to Trump, and a busy M&A week - Scorecard - MDSpire

Biotech investors’ plea to Trump, and a busy M&A week

  • By

  • Elaine Chen

  • Adam Feuerstein

  • Allison DeAngelis

  • April 2, 2026

  • 0 min

Share

Clinical Scorecard: Biotech Investors Urge Regulatory Changes from Trump Amidst Active M&A Activity

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationBroader population of patients affected by obesity and rare diseases
Care Setting

Key Highlights

  • Add specific requests from the industry-patient coalition to the FDA.

Guideline-Based Recommendations

Diagnosis

  • Include diagnostic criteria for obesity and rare diseases.

Management

  • Outline management strategies for obesity and rare diseases.

Monitoring & Follow-up

  • Suggest monitoring protocols for patients on new treatments.

Risks

  • Identify potential risks associated with obesity treatments and rare disease drugs.

Patient & Prescribing Data

Patients with obesity and rare diseases

Eli Lilly's obesity pill approval indicates a shift in treatment options

Clinical Best Practices

  • Include best practices for prescribing Eli Lilly's obesity pill.

References

Original Source(s)

Biotech investors’ plea to Trump, and a busy M&A week

  • by Elaine Chen, Adam Feuerstein, Allison DeAngelis

  • April 2, 2026

Related Content

Linking Stages of Cardiovascular-Kidney-Metabolic Syndrome to All-Cause Mortality Risk in U.S. Adults: Findings from a NHANES Cross-Sectional Analysis

GLP-1 Analysis: Riding the Wave of Peptide Innovation

The remarkable commercial success of GLP-1 receptor agonists is fueling investment, accelerating science, and creating new analytical challenges. Here, we outline the hurdles these peptides present, explore methods for impurity profiling and structural characterization, and consider strategies to keep pace with this fast-moving field.

Fresh turmoil at the FDA with Prasad’s exit